LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ:CYTR) today announced that David R. Parkinson, M.D., has joined the Company’s Clinical Advisory Board. Dr. Parkinson is an internationally known oncology authority who formerly held senior executive positions in oncology research and drug development at Biogen Idec, Amgen and Novartis AG. He has served as Acting Associate Director of the Cancer Therapy Evaluation Program at the National Cancer Institute and is a past Chairman of the U.S. Food & Drug Administration (FDA) Biologics Advisory Committee. Dr. Parkinson was recently elected to the Board of Directors of the American Association of Cancer Research.
